High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of …
AL Petzer, E Hochenburger, M Haun… - … of Hematotherapy & …, 2002 - liebertpub.com
The objective of this study was to analyze the mobilization kinetics of normal (BCR-ABLneg)
and malignant (BCR-ABLpos) progenitor cells using a new, low toxic, out-patient-based …
and malignant (BCR-ABLpos) progenitor cells using a new, low toxic, out-patient-based …
High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of …
AL Petzer, E Hochenburger, M Haun… - … & stem cell …, 2002 - pubmed.ncbi.nlm.nih.gov
The objective of this study was to analyze the mobilization kinetics of normal (BCR-ABL
(neg)) and malignant (BCR-ABL (pos)) progenitor cells using a new, low toxic, out-patient …
(neg)) and malignant (BCR-ABL (pos)) progenitor cells using a new, low toxic, out-patient …
High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of …
AL Petzer, E Hochenburger, M Haun… - … of Hematotherapy & …, 2002 - europepmc.org
The objective of this study was to analyze the mobilization kinetics of normal (BCR-ABL
(neg)) and malignant (BCR-ABL (pos)) progenitor cells using a new, low toxic, out-patient …
(neg)) and malignant (BCR-ABL (pos)) progenitor cells using a new, low toxic, out-patient …